Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 364,245
  • Shares Outstanding, K 7,044
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,802 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.8600 +15.27%
on 03/04/25
59.1600 -12.59%
on 02/18/25
-8.8000 (-14.54%)
since 02/14/25
3-Month
40.6500 +27.21%
on 01/28/25
66.7600 -22.54%
on 02/13/25
-6.6600 (-11.41%)
since 12/13/24
52-Week
1.2900 +3,908.53%
on 04/30/24
108.0000 -52.12%
on 10/18/24
+49.9300 (+2,805.06%)
since 03/14/24

Most Recent Stories

More News
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNAâ„¢ Technology

DRUG : 35.78 (-0.78%)
AIFF : 4.25 (+22.83%)
DRUG.CN : 51.7100 (unch)
Bright Minds is Unaware of Any Material Changes

Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO, Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") wishes to confirm that...

DRUG : 35.78 (-0.78%)
DRUG.CN : 51.7100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders...

See More

Key Turning Points

3rd Resistance Point 51.7100
2nd Resistance Point 51.7100
1st Resistance Point 51.7100
Last Price 51.7100
1st Support Level 51.7100
2nd Support Level 51.7100
3rd Support Level 51.7100

See More

52-Week High 108.0000
Fibonacci 61.8% 67.2368
Fibonacci 50% 54.6450
Last Price 51.7100
Fibonacci 38.2% 42.0532
52-Week Low 1.2900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar